Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor

To study and detect immunohistochemical expression of Estrogen Receptors, Progestrone Receptors and HER-2/neu Receptors in Endometrial Carcinoma (EC) and to find their associations with histological types, grades and stages of the tumor. A cross sectional study of one year duration from January 2016...

Full description

Saved in:
Bibliographic Details
Published in:Pakistan journal of medical sciences 2018-03, Vol.34 (2), p.266-271
Main Authors: Waqar, Samina, Khan, Saleem Ahmad, Sarfraz, Tariq, Waqar, Saba
Format: Article
Language:English
Subjects:
Analysis
Cancer therapies
Carcinoma
Chemotherapy
Endometrial cancer
Esophagus
Estrogens
Histochemistry
Histopathology
Hospitals
Medical schools
Obstetrics
Original
Phenols (Class of compounds)
Progesterone
Sample size
Tumors
Womens health
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To study and detect immunohistochemical expression of Estrogen Receptors, Progestrone Receptors and HER-2/neu Receptors in Endometrial Carcinoma (EC) and to find their associations with histological types, grades and stages of the tumor. A cross sectional study of one year duration from January 2016 to January 2017 was conducted at Histopathology department of Army Medical College, Rawalpindi. A non-probability purposive sampling technique was used to include 56 cases of EC. The specimens were tested for ER, PR and HER-2/neu expression using immunohistochemical analysis. Data was analyzed in SPSS and the significance of association of expression of the receptors with histological types, grades and stages of the tumor was assessed. Significant association of Her-2/neu overexpression with histological types and grades of EC was seen, whereas the association of ER and PR expression with histological types, grades and stage of EC was statistically insignificant. It is suggested that EC showing over expression of HER2/neu with immunohistochemistry may be treated with anti HER-2/neu treatment with better chances of survival and decreased post-treatment morbidity.
ISSN:1682-024X
1681-715X
DOI:10.12669/pjms.342.13637